7Baggers
 KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C.  GlobeNewswire Thu, 02 Oct 2025 11:19:57 GMT
 Kyverna Therapeutics Announces Board Member Resignation  MSN Sun, 28 Sep 2025 05:29:08 GMT
 Kyverna Therapeutics stock rating reiterated at Buy by H.C. Wainwright  Investing.com Nigeria Fri, 26 Sep 2025 00:14:15 GMT
 Kyverna Therapeutics announces board resignation and committee changes  Investing.com Thu, 25 Sep 2025 20:36:16 GMT
 Kyverna Therapeutics stock rating reiterated at Buy by H.C. Wainwright  Investing.com India Thu, 25 Sep 2025 18:57:38 GMT
 will kyverna therapeutics (nasdaq:kytx) spend its cash wisely?  富途牛牛 Sun, 21 Sep 2025 14:41:34 GMT
 Will Kyverna Therapeutics (NASDAQ:KYTX) Spend Its Cash Wisely?  富途牛牛 Sat, 20 Sep 2025 07:00:00 GMT
 published on: 2025-09-16 22:03:28  خودرو بانک Tue, 16 Sep 2025 18:34:39 GMT
 Kyverna to present phase 2 myasthenia gravis data at AANEM meeting  Investing.com Mon, 15 Sep 2025 07:00:00 GMT
 j.p. morgan maintains kyverna therapeutics(kytx.us) with buy rating  富途牛牛 Sat, 13 Sep 2025 13:22:26 GMT
 New Remission Data on MG Patients Compelling  streetwisereports.com Fri, 05 Sep 2025 07:00:00 GMT
 published on: 2025-09-04 02:45:21  Newser Thu, 04 Sep 2025 07:45:21 GMT
 published on: 2025-09-03 22:39:17  Newser Thu, 04 Sep 2025 03:39:17 GMT
 Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial  streetwisereports.com Wed, 03 Sep 2025 07:00:00 GMT
 ‘FDA-aligned’ trial of KYV-101 for MG likely to start enrolling this year  Myasthenia Gravis News Tue, 02 Sep 2025 07:00:00 GMT
 J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating  富途牛牛 Tue, 02 Sep 2025 07:00:00 GMT
 published on: 2025-09-02 01:21:00  Newser Tue, 02 Sep 2025 06:21:00 GMT
 published on: 2025-08-30 21:18:16  Newser Sun, 31 Aug 2025 02:18:16 GMT
 published on: 2025-08-30 13:27:05  Newser Sat, 30 Aug 2025 18:27:05 GMT
 published on: 2025-08-30 08:25:38  beatles.ru Sat, 30 Aug 2025 04:25:38 GMT
 published on: 2025-08-29 13:16:26  Newser Fri, 29 Aug 2025 18:16:26 GMT
 kyverna:hc wainwright raises buy rating to $10, pt up from $5  AInvest Fri, 29 Aug 2025 12:48:01 GMT
 published on: 2025-08-29 04:01:00  Newser Fri, 29 Aug 2025 09:01:00 GMT
 published on: 2025-08-28 23:26:51  Newser Fri, 29 Aug 2025 04:26:51 GMT
 published on: 2025-08-28 23:26:28  Newser Fri, 29 Aug 2025 04:26:28 GMT
 published on: 2025-08-28 21:52:45  Newser Fri, 29 Aug 2025 02:52:45 GMT
 published on: 2025-08-28 12:29:37  Newser Thu, 28 Aug 2025 17:29:37 GMT
 published on: 2025-08-28 12:10:16  Newser Thu, 28 Aug 2025 17:10:16 GMT
 published on: 2025-08-28 12:04:44  Newser Thu, 28 Aug 2025 17:04:44 GMT
 published on: 2025-08-28 05:06:16  Newser Thu, 28 Aug 2025 10:06:16 GMT
 equities analysts issue forecasts for kytx q3 earnings  MarketBeat Thu, 28 Aug 2025 08:01:04 GMT
 published on: 2025-08-28 00:29:48  Newser Thu, 28 Aug 2025 05:29:48 GMT
 published on: 2025-08-28 00:10:14  Newser Thu, 28 Aug 2025 05:10:14 GMT

Kyverna Therapeutics Inc
(NASDAQ:KYTX) 

KYTX stock logo

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2024.

Founded: 2018
Sector: TECHNOLOGY
Industry: GENERAL

Share this website to your friends